文献速递白血病造血干细胞移植与细胞治疗

NKTR-255联合CD19-22 CAR T细胞治疗难治性B细胞急性淋巴细胞白血病的1期临床试验

A phase 1 clinical trial of NKTR-255 with CD19-22 CAR T-cell therapy for refractory B-cell acute lymphoblastic leukemia.
PubMed 文献 · Blood · 2024-01-01

这项1期临床试验评估了新型重组聚合物偶联IL15受体激动剂NKTR-255联合CD19-22 CAR-T细胞治疗成人复发/难治性B细胞急性淋巴细胞白血病的安全性和疗效。11例患者入组,9例成功接受CAR19-22后序贯NKTR-255,未观察到剂量限制性毒性,8/9例(89%)达到可测量残留病灶阴性缓解,12个月无进展生存率为67%(历史对照为38%)。

要点

  • NKTR-255联合CAR19-22未出现剂量限制性毒性,最常见可能相关毒性为短暂发热和骨髓抑制。
  • 9例可评估患者中8例(89%)达到可测量残留病灶阴性缓解。
  • 12个月无进展生存率NKTR-255组为67%,历史对照为38%。

核心结论

  • NKTR-255联合CAR19-22是安全、可行的,并与高比例的持久缓解相关。

研究设计与样本

  • 1期临床试验,入组11例成人复发/难治性B细胞急性淋巴细胞白血病患者,其中9例成功接受CAR19-22后序贯NKTR-255。
  • 试验注册号为NCT03233854。

主要发现

  • 未观察到剂量限制性毒性,最常见的可能相关毒性为短暂发热和骨髓抑制。
  • 9例可评估患者中8例(89%)达到可测量残留病灶阴性缓解。
  • 12个月无进展生存率NKTR-255组为67%,历史对照为38%,NKTR-255组为历史对照的两倍。
  • 细胞因子谱显示IL15及趋化因子CXCL9和CXCL10显著升高。
  • 趋化因子升高与血液中绝对淋巴细胞计数和CD8+ CAR-T细胞减少以及脑脊液CAR-T细胞增加10倍相关,提示淋巴细胞向组织迁移。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Although chimeric antigen receptor (CAR) T-cell (CAR-T) therapy has revolutionized the treatment of B-cell malignancies, many patients relapse and therefore strategies to improve antitumor immunity are needed. We previously designed a novel autologous bispecific CAR targeting CD19 and CD22 (CAR19-22), which was well tolerated and associated with high response rates but relapse was common. Interleukin-15 (IL15) induces proliferation of diverse immune cells and can augment lymphocyte trafficking. Here, we report the results of a phase 1 clinical trial of the first combination of a novel recombinant polymer-conjugated IL15 receptor agonist (NKTR-255), with CAR19-22, in adults with relapsed/refractory B-cell acute lymphoblastic leukemia. Eleven patients were enrolled, 9 of whom successfully received CAR19-22 followed by NKTR-255. There were no dose-limiting toxicities, with transient fever and myelosuppression as the most common possibly related toxicities. We observed favorable efficacy with 8 of 9 patients (89%) achieving measurable residual disease-negative remission. At 12 months, progression-free survival for NKTR-255 was double that of historical controls (67% vs 38%). We performed correlative analyses to investigate the effects of IL15 receptor agonism. Cytokine profiling showed significant increases in IL15 and the chemokines CXCL9 and CXCL10. The increase in chemokines was associated with decreases in absolute lymphocyte counts and CD8+ CAR T cells in the blood and 10-fold increases in cerebrospinal fluid CAR-T cells, suggesting lymphocyte trafficking to tissue. Combining NKTR-255 with CAR19-22 was safe, feasible, and associated with high rates of durable responses. This trial was registered at www.clinicaltrials.gov as #NCT03233854.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Srinagesh H, Jackson C, Shiraz P, et al. A phase 1 clinical trial of NKTR-255 with CD19-22 CAR T-cell therapy for refractory B-cell acute lymphoblastic leukemia. Blood. 2024. PMID: 38968138. doi:10.1182/blood.2024024952

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。